Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 3 institutions in 1 country.
Thomas E WoodDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA.ORCID 0000-0002-8732-7895
Kathleen A WesterveltDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA.
Jessica M YoonDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA.
Heather D EshlemanDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA.
Roie LevyDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA.
Henry BurnesDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA.
Daniel J SladeDepartment of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.ORCID 0000-0001-5634-7220
Cammie F LesserDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA.ORCID 0000-0002-1702-6333
Marcia B GoldbergDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA.ORCID 0000-0003-4266-9733
Harvard University · USMassachusetts General Hospital · USVirginia Tech · US
Funding
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
Molecular signaling in Shigella disseminationR01AI081724 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 2010 to 2026
$7.1M
TRAINING IN TRANSPLANTATION BIOLOGYT32AI007529 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MADSEN, JOREN C · 1998 to 2024
$6.4M
Modeling mechanisms of Shigella pathogenesis in yeastR01AI064285 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LESSER, CAMMIE · 2006 to 2017
$4.0M
Bacteriology PhD Training ProgramT32AI132120 · NIAID · HARVARD MEDICAL SCHOOL · PI RUDNER, DAVID Z · 2017 to 2021
$1.7M
Manipulation of the mTOR signaling pathway by the Shigella effector protein OspBF32AI131582 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ESHLEMAN, HEATHER · 2018 to 2018
The type III secretion system is required for virulence of many pathogenic bacteria. Bacterial effector proteins delivered into target host cells by this system modulate host signaling pathways and processes in a manner that promotes infection. Here, we define the activity of the effector protein OspB of the human pathogen
Indexed as
Cysteine ProteasesDysentery, BacillaryShigellaAnimalsArginineBacterial ProteinsCysteineHistidineMammalsMechanistic Target of Rapamycin Complex 1Saccharomyces cerevisiaeShigella flexneriType III Secretion SystemsArginineBacterial ProteinsCysteineCysteine ProteasesHistidineMechanistic Target of Rapamycin Complex 1Type III Secretion Systemscatalytic dyadcysteine proteaseinositol hexakisphosphateOspBShigellaTco89pTORC1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.